

Shifting PrEP Initiation from Practitioner to Nurse

1 **Shifting PrEP Initiation from Practitioner to Nurse: a clinic-level multi-modal intervention**
2 **protocol to increase PrEP uptake among women at increased risk of HIV acquisition in a**
3 **U.S. OB/GYN clinical setting**

4
5 Erin L. Gingher, RN, MS, MHS
6 Timothee F. Fruhauf, MD, MPH
7 Saumya S. Sao, BA
8 Runzhi Wang, MD, MHS
9 Jenell S. Coleman, MD, MPH*

10
11 *Corresponding Author: Jenell Coleman, colemanj@jhmi.edu

12 *Disclosures*

13 E.G. and J.C. were funded in part by Gilead Sciences.

14 The remaining authors report no financial interests or potential conflicts of interest.

15 *Acknowledgements*

16 The authors would like to acknowledge the GYN/OB clinic staff for their assistance with this
17 study.

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Shifting PrEP Initiation from Practitioner to Nurse

42 **Abstract**

43 Women comprise 20% of new HIV diagnoses in the U.S. with 86% attributed to heterosexual
44 contact, but HIV pre-exposure prophylaxis (PrEP) uptake is low. OB/GYN clinics are ideal
45 settings to increase HIV prevention counseling for cisgender women, as patients are more likely
46 to discuss their sexual behavior, undergo sexually transmitted infection screening, and receive
47 risk reduction counseling. Our study will assess the feasibility, acceptability, and effectiveness of
48 a registered nurse (RN)-led PrEP project in OB/GYN clinics. Microlearning and Plan-Do-Study-
49 Act cycles will be performed, followed by a randomized controlled trial (RCT). A total of
50 cisgender women determined to be at-risk for HIV will be randomized to standard of care with
51 electronic medical record enhancements (e-SOC) or e-SOC with contact and PrEP counselling
52 by an RN, who will be able to prescribe PrEP under protocol guidance. By shifting HIV PrEP
53 counselling to a nurse, clinics may be able to increase PrEP awareness and uptake.

54

55 *Key words:* pre-exposure prophylaxis (PrEP), HIV prevention, Ending the HIV Epidemic (EHE),
56 nurse, women

57

58 Registered with clinicaltrials.gov: NCT05095818

Shifting PrEP Initiation from Practitioner to Nurse

59 **Shifting PrEP Initiation from Practitioner to Nurse: a clinic-level multi-modal intervention** 60 **protocol to increase PrEP uptake among women at increased risk of HIV acquisition in a** 61 **U.S. OB/GYN clinical setting**

62

63 **Background**

64 HIV remains a significant public health threat in the United States (U.S.). Despite
65 increased testing, prevention, and treatment services, the number of Americans newly infected
66 with HIV remains stable, with approximately 38,000 diagnosed each year (HIV.gov, 2021).
67 Women¹ represent nearly one in five of these new diagnoses, and Black women are
68 disproportionately affected (60%) (Carley et al., 2019).

69 There are currently several effective HIV prevention strategies, including needle
70 exchange programs, consistent condom use, and prevention medications, such as pre-exposure
71 prophylaxis (PrEP) and post-exposure prophylaxis (PEP). In 2010, the iPrEx study reported
72 reduced risk of HIV acquisition with oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
73 among HIV-seronegative men and transgender women who have sex with men (Grant et al.,
74 2010). Shortly thereafter, the U.S. Food and Drug Administration (FDA) approved once daily
75 oral FTC/TDF as PrEP for HIV prevention in 2012 (FDA, n.d.). With high daily adherence, PrEP
76 is over 90% effective at preventing HIV acquisition. The U.S. Public Health Service released a
77 2021 clinical practice guideline update for PrEP that recommends informing all sexually active
78 adults and adolescents about PrEP. Despite the proven effectiveness of PrEP, utilization remains
79 low among heterosexual women. In 2018, only 7% of women in the U.S. who could benefit from
80 PrEP were prescribed it (CDC, 2021).

¹For the purposes of this paper, the term “women” will refer to people assigned female at birth

Shifting PrEP Initiation from Practitioner to Nurse

81 Multilevel barriers are associated with poor PrEP uptake among women. At the patient
82 level, barriers include minimal knowledge of PrEP and underestimation of HIV acquisition risk
83 (Aaron et al., 2018; Auerbach et al., 2015; Johnson et al., 2020; Ojikutu & Mayer, 2019). In a
84 study that surveyed urban obstetrics & gynecology (OB/GYN) clinics in Louisiana, the majority
85 of patients perceived their risk of HIV acquisition to be low, despite known risk factors, such as
86 inconsistent condom use with sexual activity in a region of high HIV prevalence (Carley et al.,
87 2019). Another study assessing the sexual behavior of pregnant women in Washington, D.C.
88 found no association between the number of behavioral risk factors and perceived risk of HIV
89 acquisition (Scott et al., 2021).

90 Once informed about PrEP, women express concern over potential side effects, dislike of
91 swallowing pills, and costs. The burden of frequent healthcare appointments and stigma
92 associated with taking a medication used by people living with HIV may also impede adoption
93 of PrEP (Collier et al., 2017; Hirschhorn et al., 2020). Interpersonal relationships, such as the
94 influence of sexual partners and practitioners, have also been identified as potential individual-
95 level barriers to PrEP (Ogunbajo et al., 2021)

96 Furthermore, barriers at the practitioner-level exist, including discomfort in taking a
97 sexual history, decreasing clinic visit length, competing clinical demands, and lack of knowledge
98 (O’Byrne et al., 2019). However, even when practitioners are knowledgeable about PrEP, uptake
99 is low. For example, in our own clinics, we found that approximately 10% of pregnant patients
100 were eligible for PrEP, but none were given prescriptions (Fruhauf & Coleman, 2017). With an
101 understanding of the PrEP barriers for heterosexual women and the federal government’s *Ending*
102 *the HIV Epidemic* (EHE) Initiative, which aims to reduce the number of new HIV infections by

Shifting PrEP Initiation from Practitioner to Nurse

103 at least 90 percent by 2030, we sought to increase PrEP awareness and uptake in our outpatient
104 OB/GYN clinics.

105 This manuscript describes our clinic-level multi-modal intervention protocol to increase
106 HIV prevention services within OB/GYN clinical settings. We plan to conduct microlearning
107 sessions, Plan-Do-Study-Act cycles, and a pragmatic randomized controlled trial (RCT).

108 **Methods**

109 **Setting**

110 This project will be launched in three OB/GYN outpatient clinics of a single academic
111 medical system in Baltimore, Maryland, which has a Black majority population and a poverty
112 rate of over 20% (U.S. Census Bureau, n.d.). In 2018, Baltimore City had an estimated HIV
113 incidence rate of 42.1 per 100,000 population (CDC, 2020). It is one of the 57 jurisdictions
114 targeted in the EHE Initiative (HIV.gov, 2020). The clinics offer general obstetric and
115 gynecologic care, with some providing specialized care for high-risk pregnancies. We selected
116 an outpatient OB/GYN setting because it is where women routinely receive STI counseling,
117 testing, and treatment. Data has shown that STIs increase the risk of HIV acquisition and
118 transmission (Ward & Rönn, 2010). Furthermore, HIV incidence among pregnant and
119 postpartum women is 2-4 times higher than the rates outside of pregnancy, likely due to
120 behavioral and biological changes during this time period (Mugo et al., 2011; Thomson et al.,
121 2018). Therefore, regularly scheduled obstetric and annual gynecologic visits are opportunities
122 for healthcare practitioners to discuss sexual health and HIV-risk behaviors with patients.

123 **Patients**

124 Patients will be included in the project if they are assigned female at birth, not living with
125 HIV, and are receiving OB/GYN care in our preselected clinics. Obstetric patients will be

Shifting PrEP Initiation from Practitioner to Nurse

126 identified through an existing non-validated STI/HIV risk assessment tool embedded into our
127 electronic medical record (EMR) (**Table 1**), which is completed by an RN during a patient's
128 initial prenatal care visit. This tool was developed over a decade ago as part of general
129 behavioral risk assessment for obstetrics patients, and not specifically for PrEP eligibility.
130 Eligible gynecologic patients will be identified by a positive STI diagnosis within the past 6
131 months, or if seeking STI testing and have a history of an STI (either self-reported or resulted in
132 the EMR). Because PrEP eligibility criteria (**Table 2**) differ by guidelines and expert opinion, we
133 selected broad criteria given the high HIV prevalence in our area (U.S. Public Health Service,
134 2018; The American College of Obstetricians and Gynecologists [ACOG], 2014). Before PrEP is
135 prescribed, PrEP contraindications will be followed, including: symptoms or clinical signs
136 consistent with acute HIV infection, unknown HIV infection status, allergies to the active
137 substances or any excipients of PrEP, estimated creatinine clearance of <60 mL/minute, active
138 Hepatitis B infection, or are participating in other clinical studies related to HIV and/or
139 antiretroviral therapy.

140 **Study design**

141 The study is designed with several, sequential methodologic components because of our
142 organizational culture and prior data that suggest complex, multi-level barriers to PrEP uptake
143 among women. First, we will synthesize the existing literature, engage key stakeholders, and
144 conduct microlearning sessions about PrEP. Microlearning sessions involve the delivery of
145 educational content that is brief, targeted, and occur within clinical sites (Buchem &
146 Hamelmann, 2010). Microlearning sessions will be conducted among all healthcare team
147 members in the clinic, which includes nurses, medical assistants, nurse practitioners, midwives,
148 and physicians. Then, Plan-Do-Study-Act (PDSA) will be used. The PDSA method is a

Shifting PrEP Initiation from Practitioner to Nurse

149 commonly used improvement process in health care settings, which utilizes small tests of change
150 to optimize a process (Coury et al., 2017). A common misperception with PDSA methodology is
151 that it is a standalone method (Reed & Card, 2016). Therefore, we designed multiple rigorous
152 methodologies to include along with PDSA.

153 The first PDSA cycle will involve EMR changes and identification of a registered nurse
154 (RN) who will be trained to initiate PrEP. Our prior data has shown that PrEP is rarely discussed
155 or prescribed to patients, despite indications (Fruhauf & Coleman, 2017; Lopez et al., 2019).
156 Proposed EMR changes will include the creation of (1) Best practice alerts (BPAs) that
157 encourage nurses and practitioners to add HIV risk-related ICD-10 codes to the problem lists.
158 Problem lists contain a summary snapshot of the patient’s medical conditions for use by all
159 practitioners. A positive risk screen for prenatal care patients will alert the nurse to add “HIV
160 risk factors complicating pregnancy” to the patient’s problem list during the initial prenatal visit.
161 When a patient tests positive for an STI and is prescribed an antibiotic for treatment, a BPA will
162 alert the GYN practitioner that the patient may have HIV acquisition risk factors and to add
163 “encounter for HIV counseling” to the problem list; (2) Comprehensive and easily accessible
164 order sets that facilitate initiation of PrEP by outlining the required laboratory tests and their
165 timing, and the exact FTC/TDF medication instructions to avoid incorrect prescriptions; (3) Note
166 templates that allow for consistent documentation and serve as an educational tool to ensure
167 adequate HIV prevention counseling is complete; (4) PrEP patient educational material to
168 include in patient after-visit summaries, which are given to patients at the conclusion of clinic
169 appointments. Educational materials include frequently asked questions (FAQ), FTC/TDF
170 medication facts, and PrEP use during pregnancy or breastfeeding; and (5) short animation
171 videos that describe PrEP.

Shifting PrEP Initiation from Practitioner to Nurse

172 We will identify a PrEP-RN who will undergo training in HIV prevention, including the
173 use of PrEP. Well within the scope of nursing practice, RNs can screen patients for risk factors,
174 counsel and educate at-risk patients about effective HIV prevention strategies, and advocate for
175 PrEP utilization. To our knowledge, this is the first U.S. RN-led PrEP program for women
176 exclusively. One novel aspect of our program is that our PrEP-RN will be able to initiate
177 laboratory test ordering and PrEP prescriptions, under specific protocol guidance and supervision
178 by the clinic's Medical Director. Another innovative aspect is that we designed our PrEP-RN
179 program to allow for telehealth counseling sessions for initiation and follow-up sessions via
180 telephone or video. Patients are only required to visit a brick-and-mortar location to complete
181 laboratory tests, which can take place at a location most convenient for them.

182 Other models for RN-led PrEP programs have been developed in Canada, but none focus
183 exclusively on women, take place in an OB/GYN outpatient setting where women prefer to
184 receive information about HIV prevention, or allow telehealth (Auerbach et al., 2015;
185 Hirschhorn et al., 2020; Sharma et al., 2018). As O'Byrne highlights in their PrEP-RN model,
186 the numerous appointments involved with the first year of PrEP use has a high potential for
187 missed appointments, which may be remedied by the use of telehealth (O'Byrne et al., 2019).

188 The second PDSA cycle will incorporate feedback from the first cycle and then deploy
189 the PrEP-RN intervention at the main outpatient clinic site. Subsequent PDSA cycles will
190 include roll-out of the project at the remaining clinical sites with protocol adjustments, as needed
191 based on the prior PDSA cycle. To test whether an RN can effectively counsel patients about
192 PrEP, initiate therapy, and follow patients with minimal practitioner involvement, we plan to
193 conduct a pragmatic randomized controlled trial (RCT). A pragmatic (effectiveness) trial was
194 selected to generate evidence that would be applicable in a real-world clinical practice setting

Shifting PrEP Initiation from Practitioner to Nurse

195 and increase external validity. The control arm will include an enhanced standard of care (e-
196 SOC), which is standard of care plus the EMR changes. The intervention arm will include the
197 PrEP-RN plus e-SOC.

198 Patients randomized to the intervention arm will first be contacted via an electronic
199 patient portal integrated with the EMR that allows patients access to their medical records and a
200 messaging system to communicate with practitioners. While most of our patients utilize this
201 patient portal, if a patient does not have access, this step will be skipped.

202 Follow-up telephone calls will then be made to counsel patients on HIV risk factors in
203 general, their HIV risk factors in particular, and prevention methods, inclusive of PrEP. PrEP,
204 including same-day PrEP, will be offered. If the required laboratory tests have not been obtained
205 in the past month, the PrEP-RN will place and order the laboratory tests. The PrEP-RN will
206 utilize the PrEP order set in the EMR to order labs, prescribe medication electronically to the
207 patient's pharmacy, provide patient education, and schedule follow-up appointments. All orders
208 and prescriptions are sent to the clinic's Medical Director for authorization. Standardized
209 smartphrases for clinical notes will also be utilized to record the interaction by the PrEP-RN with
210 the study participants.

211 If a patient declines PrEP, no further attempts are made by the PrEP-RN to counsel the
212 patient. Additional educational material may be sent via the electronic patient portal as desired
213 by the patient. The patient is encouraged to contact the PrEP-RN, via telephone or the electronic
214 patient portal, if she has any future questions or decides to use PrEP.

215 A Manual of Procedures (**Appendix A**) was created for the PrEP-RN to carry out each
216 step of PrEP initiation and follow up. The manual outlines how to respond to abnormal tests,
217 provide prescription coverage assistance, and coordinate care with other specialties as needed to

Shifting PrEP Initiation from Practitioner to Nurse

218 address test results. The PrEP-RN will be responsible for follow-up visits and will contact the
219 patients one-two weeks after medication initiation. At this time, the PrEP-RN will review the
220 importance of daily adherence to PrEP and assess for any side effects.

221 **Randomization and blinding**

222 Stratified block randomization will be used to allocate eligible patients into the
223 intervention and control arms with a 1:1 ratio. Patients will be classified by patient type
224 (obstetric or gynecologic) and clinics. To avoid imbalance between the two study arms, the same
225 type of patients from the same site will be randomized within a block that comprise four ordered
226 assignments. SAS will be used to generate the randomization table. EMR data abstracts will be
227 obtained biweekly to identify PrEP eligible patients. A member of the study team will assign
228 these PrEP eligible patients to an intervention arm based on the randomization allocation per
229 patient type and site. Practitioners will be blinded to study assignment to prevent interference in
230 the standard of care delivery.

231 **Ethics Approval and Waiver of Consent to Participate**

232 The study received approval from the Institutional Review Board (IRB) of Johns Hopkins
233 Medicine. Although the primary purpose of the project was to improve patient outcomes, the
234 IRB reviewed the project as research because we included randomization plus an external
235 funding source. However, a waiver of consent was granted because the study involves no more
236 than minimal risk to the subjects, the waiver does not adversely affect the rights or welfare of the
237 subjects, and the research could not be practicably completed without the waiver.

238 **Sample size estimate**

239 To test the effectiveness of the PrEP-RN, we estimate that we will require 440 patients
240 (220 women per arm). The sample size was selected to provide 80% power to detect an effect

Shifting PrEP Initiation from Practitioner to Nurse

241 size of 15% between the control and intervention group, at an alpha level of 0.05 using two-sided
242 test. The PrEP-RN intervention and EMR prompts will cease once the sample size has been
243 reached.

244 **Outcomes**

245 The project will be evaluated using the Reach, Effectiveness, Adoption, Implementation,
246 and Maintenance (RE-AIM) framework. RE-AIM has five domains: Reach the target population
247 with the intervention; Effectiveness or impact of the intervention; Adoption by target patients,
248 staff, clinics; Implementation of the intervention, including consistency of delivery; and
249 Maintenance of the intervention over the long term (RE-AIM, n.d.). The Reach and
250 Effectiveness domains are individual-level factors, while the Adoption and Implementation
251 domains are systems-level factors. The Maintenance domain includes both individual- and
252 systems-level factors.

253 **Primary Outcomes**

254 The primary outcome estimated by the RCT will be awareness of PrEP, measured by the
255 percentage of at-risk women with EMR documentation of HIV risk prevention counseling.

256 **Secondary Outcomes**

257 Secondary outcomes will include feasibility, which will be defined as reaching the target
258 goal in at least 3 of the RE-AIM domains (**Table 3**). Other secondary outcomes include the
259 percentage of women at risk for HIV who initiate PrEP during the study interval and the
260 percentage of women who are using PrEP at 3-, 6-, 9-, and 12-months from initiation. PrEP
261 initiation will be measured by the number of PrEP laboratory tests and the number of PrEP
262 prescriptions ordered. We will also assess the utilization of EMR enhancements, measured as the

Shifting PrEP Initiation from Practitioner to Nurse

263 percentage of patients with an HIV-risk diagnosis added to their EMR problem list. Last, we will
264 evaluate the acceptability of the PrEP-RN intervention among our study population.

265 **Acceptability**

266 Acceptability of and satisfaction with the PrEP-RN intervention will be evaluated using a
267 brief survey of a randomly selected group of patients (n=25) who received the PrEP-RN
268 intervention within the previous three months (**Table 4**). Items related to patient satisfaction and
269 telehealth acceptability were identified through a review of the literature (Weaver et al., 2021;
270 Yip et al., 2003; Gwady-Sridhar et al., 2003).

271 **Risks and monitoring**

272 The intervention does not pose any greater risks than routine clinical care, and no
273 participant will receive less than e-SOC. Because the intervention is integrated at the clinic level
274 and poses minimal risk, we do not have an independent data monitoring committee. The team
275 will report any adverse events to the IRB. To ensure the quality of our counseling intervention,
276 we will have weekly check-ins with the PrEP RN, research staff, and the study Principal
277 Investigator to discuss any issues in counseling patients and incorporate patient feedback on an
278 ongoing basis.

279 **Statistical Analysis**

280 Sociodemographic characteristics of the study population will be reported using
281 descriptive statistics. For the RCT, statistical analysis will be performed based on the intention-
282 to-treat principle. We will compare the percentage of at-risk women with EMR documentation of
283 HIV risk prevention counseling (i.e. primary outcome), percentage of women at risk for HIV
284 who initiate PrEP during the study interval, and the percentage of women who are using PrEP at
285 3-, 6-, 9-, and 12-months from initiation between the intervention group and the control group

Shifting PrEP Initiation from Practitioner to Nurse

286 using the chi-squared test with Fisher's exact. Since participants in the two arms are expected to
287 have equal baseline characteristics due to randomization, basic confounders will not be
288 considered. However, if any baseline characteristics differ significantly between the two groups,
289 we will use regression models to control them. Additionally, among women randomized to the
290 PrEP RN, the reason for initiating or not initiating PrEP will be presented as a number and
291 percentage. Also, we will plot the percentage of women who are using PrEP for 3-, 6-, 9-, and
292 12-months to demonstrate the trend. Marginal models will be used to identify factors associated
293 with the trend. Lastly, to assess whether the interventions had a sustainable impact on
294 practitioners' behavior after withdrawing them, the primary and secondary outcomes will be
295 compared to the year before the PrEP RN project began, using the chi-squared test.

296 Discussion

297 Prevention is one of the four key strategies outlined by the federal government's EHE
298 initiative. Our novel project seeks to prevent new HIV transmissions by addressing known
299 barriers to PrEP at the patient, practitioner, and system levels.

300 OB/GYN clinics were chosen for this project for several reasons. First, women have
301 consistently expressed a preference for receiving HIV prevention services in clinics where they
302 receive OB/GYN care, as opposed to specialty clinics that treat infectious diseases or STIs where
303 most PrEP projects are located (Auerbach et al., 2015; Carley et al., 2019; Hirschhorn et al.,
304 2020). Second, despite a history of mistrust in the health care system, Black and Hispanic
305 women reported trusting their individual gynecologist (Hirschhorn et al., 2020; Kennedy et al.,
306 2007). Third, PrEP use by women in the U.S. is largely inadequate, as the PrEP-to-need ratio for
307 women is only 0.4 compared to 2.1 for men (Highleyman, 2018). Last, OB/GYN practitioners
308 manage women during heightened periods of HIV acquisition risk, such as during the course of

Shifting PrEP Initiation from Practitioner to Nurse

309 infection with an STI or during pregnancy and the postpartum period, and they routinely provide
310 sexual and reproductive care for at-risk women (ACOG, 2018).

311 Clinic nurses are well suited for PrEP counseling sessions, as they are accustomed to
312 delivering positive STI results to patients and providing risk reduction strategies. Furthermore,
313 registered nurses represent a more abundant and less expensive resource than physicians or mid-
314 level providers (American Association of Colleges of Nursing, 2019).

315 Through the role of the PrEP RN, we are utilizing telemedicine to help combat barriers to
316 PrEP awareness and initiation. Telemedicine may improve efficiency, while also providing
317 increased comfort and convenience for patients. Barriers to patient access, such as limited time
318 off from work and childcare responsibilities are minimized (Hasselfeld, n.d.; Gajarawala &
319 Pelkowski, 2021). Feasibility and efficacy, as well as patient acceptability, will be evaluated to
320 determine the overall success of the project.

321 Despite the strengths, our protocol has several limitations. Our health system has EMRs,
322 which facilitates the ease of nursing staff to place orders and prescriptions to be signed by a
323 practitioner. Systems without EMRs may find our protocol cumbersome, however, standing
324 orders may be considered instead. It is also plausible that changes in PrEP uptake could be due in
325 part to practitioner behavior changes resulting from the EMR enhancements, as opposed to the
326 PrEP-RN. Furthermore, by targeting female patients who are engaged in clinical care, we are
327 unable to reach women at-risk for HIV who do not have access to routine care. Lastly, our urban
328 high HIV prevalence location may limit the generalizability of this study.

329 Nonetheless, if this study demonstrates that a PrEP-RN can increase PrEP awareness and
330 uptake among at-risk women, we plan to test these interventions, including the EMR
331 enhancements in non-OB/GYN clinical settings. Our multimodal PrEP intervention could be

Shifting PrEP Initiation from Practitioner to Nurse

- 332 implemented in other settings and largely improve current strategies for increasing PrEP
- 333 utilization among at-risk women.

Shifting PrEP Initiation from Practitioner to Nurse

334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353

References

Aaron, E., Blum, C., Seidman, D., Hoyt, M. J., Simone, J., Sullivan, M., & Smith, D. K. (2018). Optimizing delivery of HIV preexposure prophylaxis for women in the United States. *AIDS Patient Care and STDs*, 32(1), 16–23. <https://doi.org/10.1089/apc.2017.0201>

American Association of Colleges of Nursing (AACN). (2019, April 1). Nursing fact sheet. <https://www.aacnnursing.org/News-Information/Fact-Sheets/Nursing-Fact-Sheet>

Auerbach, J. D., Kinsky, S., Brown, G., & Charles, V. (2015). Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. *AIDS Patient Care and STDs*, 29(2), 102–110. <https://doi.org/10.1089/apc.2014.0142>

Buchem, I., & Hamelmann, H. (2010, September). Microlearning: A strategy for ongoing professional development. *eLearning Papers*.

Carley, T., Siewert, E., & Naresh, A. (2019). Interest in pre-exposure prophylaxis (PrEP) for HIV is limited among women in a general obstetrics & gynecology setting. *AIDS and Behavior*, 23(10), 2741–2748. <https://doi.org/10.1007/s10461-019-02529-1>

Centers for Disease Control and Prevention (CDC). (2020, May). Estimated HIV incidence and prevalence in the United States, 2014–2018. *HIV Surveillance Supplemental Report 2020*; 25(No. 1). <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>

Centers for Disease Control and Prevention (CDC). (2021, March 8). HIV and women. <https://www.cdc.gov/hiv/group/gender/women/prep-coverage.html>

Shifting PrEP Initiation from Practitioner to Nurse

- 354 Collier, K. L., Colarossi, L. G., & Sanders, K. (2017). Raising Awareness of Pre-Exposure
355 Prophylaxis (PrEP) among Women in New York City: Community and Provider
356 Perspectives. *Journal of Health Communication*, 22(3), 183–189.
357 <https://doi.org/10.1080/10810730.2016.1261969>
- 358 Coury, J., Schneider, J. L., Rivelli, J. S., Petrik, A. F., Seibel, E., D'Agostini, B., Taplin, S. H.,
359 Green, B. B., & Coronado, G. D. (2017). Applying the Plan-Do-Study-Act (PDSA)
360 approach to a large pragmatic study involving safety net clinics. *BMC Health Services
361 Research*, Aaron, E., Blum, C., Seidman, D., Hoyt, M. J., Simone, J., Sullivan, M., &
362 Smith, D. K. (2018). Optimizing Delivery of HIV Preexposure Prophylaxis for Women in
363 the United States. *AIDS Patient Care and STDs*, 32(1), 16–23.
364 <https://doi.org/10.1089/apc.2017.0201>
- 365 Fruhauf, T., & Coleman, J. S. (2017). A missed opportunity for U.S. perinatal Human
366 Immunodeficiency Virus elimination. *Obstetrics and Gynecology*, 130(4), 703–709.
367 <https://doi.org/10.1097/AOG.0000000000002258>
- 368 Gajarawala, S. N., & Pelkowski, J. N. (2021). Telehealth Benefits and Barriers. *The Journal for
369 Nurse Practitioners*, 17(2), 218–221. <https://doi.org/10.1016/j.nurpra.2020.09.013>
- 370 Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P.,
371 Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., Montoya-Herrera, O.,
372 Fernández, T., Veloso, V. G., Buchbinder, S. P., Chariyalertsak, S., Schechter, M.,
373 Bekker, L.-G., Mayer, K. H., Kallás, E. G., ... Glidden, D. V. (2010). Preexposure
374 chemoprophylaxis for HIV prevention in men who have sex with men. *New England
375 Journal of Medicine*, 363(27), 2587–2599. <https://doi.org/10.1056/NEJMoa1011205>

Shifting PrEP Initiation from Practitioner to Nurse

- 376 Gwadry-Sridhar, F., Guyatt, G. H., Arnold, J. M. O., Massel, D., Brown, J., Nadeau, L., &
377 Lawrence, S. (2003). Instruments to measure acceptability of information and acquisition
378 of knowledge in patients with heart failure. *European Journal of Heart Failure*, 5(6),
379 783–791. [https://doi.org/10.1016/S1388-9842\(03\)00158-2](https://doi.org/10.1016/S1388-9842(03)00158-2)
- 380 Hasselfeld, B.W. (n.d.). *Benefits of Telemedicine*. Johns Hopkins Medicine Health.
381 [https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/benefits-of-](https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/benefits-of-telemedicine)
382 [telemedicine](https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/benefits-of-telemedicine)
- 383 Highleyman, L. (2018, March 7). PrEP use growing in US, but not reaching all those in need.
384 NAM: AIDSmap. [https://www.aidsmap.com/news/mar-2018/prep-use-growing-us-not-](https://www.aidsmap.com/news/mar-2018/prep-use-growing-us-not-reaching-all-those-need)
385 [reaching-all-those-need](https://www.aidsmap.com/news/mar-2018/prep-use-growing-us-not-reaching-all-those-need)
- 386 Hirschhorn, L. R., Brown, R. N., Friedman, E. E., Greene, G. J., Bender, A., Christeller, C.,
387 Bouris, A., Johnson, A. K., Pickett, J., Modali, L., & Ridgway, J. P. (2020). Black
388 cisgender women’s PrEP knowledge, attitudes, preferences, and experience in Chicago.
389 *Journal of Acquired Immune Deficiency Syndrome*, 84(5), 497-507.
390 <https://doi.org/10.1097/QAI.0000000000002377>. .
- 391 HIV.gov. (2021, June 2). What is Ending the HIV Epidemic in the U.S.?
392 <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>
- 393 HIV.gov. (2020, November 3). Priority Jurisdictions: Phase I. [https://www.hiv.gov/federal-](https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/jurisdictions/phase-one)
394 [response/ending-the-hiv-epidemic/jurisdictions/phase-one](https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/jurisdictions/phase-one)
- 395 Johnson, A. K., Fletcher, F. E., Ott, E., Wishart, M., Friedman, E. E., Terlikowski, J., & Haider,
396 S. (2020). Awareness and Intent to Use Pre-exposure Prophylaxis (PrEP) Among African

Shifting PrEP Initiation from Practitioner to Nurse

- 397 American Women in a Family Planning Clinic. *Journal of Racial and Ethnic Health*
398 *Disparities*, 7(3), 550–554. <https://doi.org/10.1007/s40615-019-00683-9>
- 399 Kennedy, B. R., Mathis, C. C., & Woods, A. K. (2007). African Americans and their distrust of
400 the health care system: Healthcare for diverse populations. *Journal of Cultural Diversity*,
401 14(2), 56–60.
- 402 Lopez, A., Belcher, H., Agwu, A. L., Fennell, J. C., Gaydos, C., & Trent, M. E. (2019). 51.
403 Unmet need for risk reduction counseling and Prep among young women at risk for HIV.
404 *Journal of Adolescent Health*, 64(2), S28.
405 <https://doi.org/10.1016/j.jadohealth.2018.10.066>
- 406 Mugo, N., Heffron, R., Donnell, D., Wald, A., Were, E., Rees, H., Celum, C., Kiarie, J., Cohen,
407 C., Kayintekore, K., Baeten, J. Increased risk of HIV-1 transmission in pregnancy: A
408 prospective study among African HIV-1 serodiscordant couples. *AIDS*, 25(15), 1887-
409 1895. doi:10.1097/QAD.0b013e32834a9338.
- 410 O’Byrne, P., MacPherson, P., Orser, L., Jacob, J. D., & Holmes, D. (2019). PrEP-RN: Clinical
411 considerations and protocols for nurse-led PrEP. *The Journal of the Association of Nurses*
412 *in AIDS Care*, 30(3), 301–311. <https://doi.org/10.1097/JNC.0000000000000075>
- 413 Ogunbajo, A., Storholm, E. D., Ober, A. J., Bogart, L. M., Reback, C. J., Flynn, R., Lyman, P.,
414 & Morris, S. (2021). Multilevel Barriers to HIV PrEP Uptake and Adherence Among
415 Black and Hispanic/Latinx Transgender Women in Southern California. *AIDS and*
416 *Behavior*, 25(7), 2301–2315. <https://doi.org/10.1007/s10461-021-03159-2>

Shifting PrEP Initiation from Practitioner to Nurse

- 417 Ojikutu, B. O., & Mayer, K. H. (2019). Hidden in Plain Sight: Identifying Women Living in the
418 United States Who Could Benefit From HIV Preexposure Prophylaxis. *The Journal of*
419 *Infectious Diseases*, 222(9), 1428–1431. <https://doi.org/10.1093/infdis/jiz416>
- 420 RE-AIM. (n.d.) What is RE-AIM. <https://www.re-aim.org/about/what-is-re-aim/>
- 421 Reed, J. E., & Card, A. J. (2016). The problem with Plan-Do-Study-Act cycles. *BMJ Quality &*
422 *Safety*, 25(3), 147–152. <https://doi.org/10.1136/bmjqs-2015-005076>
- 423 Scott, R. K., Hull, S. J., Richards, R. C., Klemmer, K., Salmoran, F., & Huang, J. C. (2021).
424 Awareness, acceptability, and intention to initiate HIV pre-exposure prophylaxis among
425 pregnant women. *AIDS Care*, 1–13. <https://doi.org/10.1080/09540121.2021.1916870>
- 426 Sharma, M., Chris, A., Chan, A., Knox, D. C., Wilton, J., McEwen, O., Mishra, S., Grace, D.,
427 Rogers, T., Bayoumi, A. M., Maxwell, J., Shahin, R., Bogoch, I., Gilbert, M., & Tan, D.
428 H. S. (2018). Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP)
429 through family physicians and sexual health clinic nurses: A dissemination and
430 implementation study protocol. *BMC Health Services Research*, 18(1), 513.
431 <https://doi.org/10.1186/s12913-018-3324-2>
- 432 The American College of Obstetricians and Gynecologists (ACOG). (2018, October). Well-
433 woman visit. ACOG Committee Opinion, 755. [https://www.acog.org/en/clinical/clinical-](https://www.acog.org/en/clinical/clinical-guidance/committee-opinion/articles/2018/10/well-woman-visit)
434 [guidance/committee-opinion/articles/2018/10/well-woman-visit](https://www.acog.org/en/clinical/clinical-guidance/committee-opinion/articles/2018/10/well-woman-visit)
- 435 The American College of Obstetricians and Gynecologists (ACOG). (2014, May; reaffirmed
436 2020). Preexposure prophylaxis for the prevention of Human Immunodeficiency Virus.
437 ACOG Committee Opinion, 595. <https://www.acog.org/en/clinical/clinical->

Shifting PrEP Initiation from Practitioner to Nurse

438 [guidance/committee-opinion/articles/2014/05/preexposure-prophylaxis-for-the-](https://www.cdc.gov/guidance/committee-opinion/articles/2014/05/preexposure-prophylaxis-for-the-prevention-of-human-immunodeficiency-virus)
439 [prevention-of-human-immunodeficiency-virus](https://www.cdc.gov/guidance/committee-opinion/articles/2014/05/preexposure-prophylaxis-for-the-prevention-of-human-immunodeficiency-virus)

440 Thomson, K., Hughes, J., Baeten, J., John-Stewart, G., Celum, C., Cohen, C., Ngunjiri, K., Kiarie,
441 J., Mugo, N., Heffron, R. (2018). Increased risk of HIV acquisition among women
442 throughout pregnancy and during the postpartum period: A prospective per-coital-act
443 analysis among women with HIV-infected partners. *The Journal of Infectious Diseases*;
444 *218*(1), 16–25, <https://doi.org/10.1093/infdis/jiy113>

445 U.S. Census Bureau. (n.d.) *QuickFacts: Baltimore city, Maryland; United States*.
446 <https://www.census.gov/quickfacts/fact/table/baltimorecitymaryland,US/PST045219>

447 U.S. Food & Drug Administration (FDA). (n.d.) Drugs@FDA: FDA-Approved Drugs.
448 [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&Ap](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021752)
449 [plNo=021752](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021752)

450 U.S. Public Health Service. (published online 2018, March). Preexposure prophylaxis for the
451 prevention of HIV infection in the United States – 2017 Update. A Clinical Practice
452 Guideline. <https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf>

453 U.S. Public Health Service. (2021). Preexposure prophylaxis for the prevention of HIV infection
454 in the United States – 2021 Update. A Clinical Practice Guideline.
455 <https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf>

456 Ward, H., & Rönn, M. (2010). The contribution of STIs to the sexual transmission of HIV.
457 *Current Opinion in HIV and AIDS*, *5*(4), 305–310.
458 <https://doi.org/10.1097/COH.0b013e32833a8844>

Shifting PrEP Initiation from Practitioner to Nurse

- 459 Weaver, M. S., Lukowski, J., Wichman, B., Navaneethan, H., Fisher, A. L., & Neumann, M. L.
460 (2021). Human connection and technology connectivity: A systematic review of available
461 telehealth survey instruments. *Journal of Pain and Symptom Management*, 61(5), 1042-
462 1051.e2. <https://doi.org/10.1016/j.jpainsymman.2020.10.010>
- 463 Yip, M.P., Chang, A.M., & Chan, J. (2003, February 1). Development of the telemedicine
464 satisfaction questionnaire to evaluate patient satisfaction with telemedicine: A
465 preliminary study. *Journal of Telemedicine and Telecare*, 9(1), 46–50.
466 <https://doi.org/10.1258/135763303321159693>
- 467

Shifting PrEP Initiation from Practitioner to Nurse

468

Key Considerations

469

- There are many reasons why PrEP uptake among American women is so low, with underestimation of HIV acquisition risk a major factor.

470

471

- HIV risk factor and prevention counseling can take place via telemedicine, which has increasingly become a popular and convenient method of healthcare delivery.

472

473

- The EMR can be utilized to alert practitioners to HIV risk factors and aid in the identification of PrEP-eligible patients.

474

475

Shifting PrEP Initiation from Practitioner to Nurse

476 **Table 1: Obstetric HIV/STI Risk Tool**

Risk factor	Response options		
Inject illicit drugs	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Sex with partner who injects illicit drugs	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Any past STIs	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Sex with a partner who has sex with both men and women	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Sex for money, drugs, other payment	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Sex with a partner currently infected with HIV	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Sex with more than one partner	Yes, in the past 6 months	Yes, more than 6 months ago	Never

477

Shifting PrEP Initiation from Practitioner to Nurse

478 **Table 2: PrEP Eligibility Criteria by Organization**

Risk Factors	ACOG	CDC	USPSTF	WHO*
Sex in high HIV-prevalence area or social network (plus at least one other risk factor)	✓			
Inconsistent or no condom use	✓	✓	✓	✓
Sexual partner with unknown HIV status	✓ (who has at least one other risk factor)		(inconsistent condom use with a partner whose HIV status is unknown and who is at high risk, such as injection drug user or man who has sex with men and women)	✓ (and partner is high risk)
Sexual partner living with HIV	✓	✓	✓	✓
STI diagnosis within past 6 months	✓ (no time frame)	✓	✓ (syphilis or gonorrhea)	✓
Injection drug use	✓	✓ (with shared injection equipment or injection partner with HIV)	✓ (with shared drug injection equipment or risk of sexual acquisition)	✓ (with shared needles/syringes)
Recreational drug use			✓ (with shared drug injection equipment or risk of sexual acquisition)	✓ (sex under the influence of recreational drugs)
Alcohol dependence	✓			✓ (sex under the influence of alcohol)
Incarceration	✓			
Transactional sex	✓			✓
Ongoing IPV/GBV				✓
Recurrent use of PEP		✓		✓

ACOG: The American College of Obstetricians and Gynecologists

CDC: Centers for Disease Control and Prevention

USPSTF: United States Preventive Services Task Force

WHO: World Health Organization

IPV: intimate partner violence

GBV: gender-based violence

PEP: post-exposure prophylaxis

*According to WHO, PrEP eligibility may vary by country. HIV-negative individuals who are “determined to be at substantial risk for HIV as defined by national guidelines” are eligible for PrEP. WHO does not list specific criteria but offers an example tool for determining eligibility. These example criteria are included in the table.

479

480

481

Shifting PrEP Initiation from Practitioner to Nurse

482

483 **Table 3. Re-AIM Evaluation**

Domain	Target
REACH	
% women with documented HIV risk counseling, including PrEP (awareness)	≥80%
EFFECTIVENESS	
% women at-risk for HIV who agree to PrEP (uptake: PrEP lab orders and prescriptions)	≥50%
% women at-risk for HIV who agree to same-day PrEP	≥30%
ADOPTION	
% of nurses adding HIV risk diagnosis to problem list	≥20
IMPLEMENTATION	
% pregnant women with completed HIV risk screen randomized	≥90%
% at-risk pregnant women with diagnosis on problem list	≥80%
% STI positive women randomized	≥90%
% STI positive women in intervention arm contacted by PrEP nurse	≥75%
MAINTENANCE	
% women at-risk for HIV using PrEP x 3 months	≥35%
% women at-risk for HIV using PrEP x 6 months	≥25%
% women at-risk for HIV using PrEP x 12 months	≥15%

484

Shifting PrEP Initiation from Practitioner to Nurse

485 **Table 4. PrEP RN Patient Acceptability Questionnaire**

486

Question	Response Options
1. Have you ever heard about PrEP (pre-exposure prophylaxis) for HIV?	1. Yes 2. No (skip to Q6)
2. If yes, who provided the information?	1. Doctor 2. Nurse 3. Friend 4. Family member 5. Other healthcare provider 6. Uncertain
3. Did they help you better understand your risk for HIV acquisition?	No, not at all (1) (2) (3) (4) (5) Yes, very much
4. Did they help you better understand HIV prevention methods, including PrEP?	No, not at all (1) (2) (3) (4) (5) Yes, very much
5. How well do you think that you understand PrEP?	Know very little (1) (2) (3) (4) (5) Very knowledgeable

For patients indicating that they received information from a nurse, these questions will specifically pertain to the telephone counseling session:

6. Do you remember receiving a phone call providing information about PrEP?	1. Yes 2. No (skip to Q8)
7. How useful was the information received from the nurse?	Not at all useful (1) (2) (3) (4) (5) Very useful
8. Were you satisfied with the telephone method of delivery for this information?	No, not at all (1) (2) (3) (4) (5) Yes, very much
9. How would you have liked to be contacted with this information (e.g., in person appointment, video visit)?	
10. Please rate your overall satisfaction with the counseling sessions.	Very dissatisfied (1) (2) (3) (4) (5) Very satisfied
11. Do you have any additional comments?	

487

Shifting PrEP Initiation from Practitioner to Nurse

488

APPENDIX A

489

PrEP RN Manual

490 The decision to prescribe PrEP is based on the clinical judgment of the nurse evaluating

491 the patient. The following is a list of steps to be followed by the PrEP RN.

492 a) *Determine Eligibility*

493 Women (assigned female at birth) ≥ 15 years old at risk for HIV infection should be

494 considered for PrEP and will be assessed for the option of same-day PrEP start.

495 • Living in (or seeking medical care) in a high HIV-prevalence area or social
496 network

497 • Inconsistent or no condom use

498 • Specific criteria for patient type:

499 ○ GYN patients:

500 ▪ current or recent (within last six months) STI diagnosis

501 ▪ lifetime history of STI and currently seeking STI testing

502 ○ OB patients: lifetime history of at least one of the following:

503 ▪ STI diagnosis

504 ▪ More than one concurrent sexual partner

505 ▪ Injection of illicit drugs

506 ▪ Sex with someone who injects illicit drugs

507 ▪ Sex with someone who has sex with both men and women

508 ▪ Sex with a partner currently living with HIV

509 ▪ Sex for money, drugs, or other payments

Shifting PrEP Initiation from Practitioner to Nurse

- 510 • If a patient is PEP (post-exposure prophylaxis)-eligible based on clinical
511 guidelines, including exposure within the past 72 hours, the patient should be
512 started on PEP and transitioned to PrEP after 1 month. Upon transition from PEP
513 to PrEP the patient needs to be reassessed for clinical signs of HIV infection and
514 labs for PrEP start need to be obtained.
- 515 • If a patient has any of the following conditions, she is not a candidate for PrEP:
- 516 ○ unknown or known HIV infection
- 517 ○ renal insufficiency (CrCl <60ml/min)
- 518 ○ active Hepatitis B infection
- 519 ○ signs or symptoms of acute HIV infection
- 520 ○ not able to strictly adhere to the treatment or monitoring protocols
- 521 ○ weight < 35 kg
- 522 ○ allergies to the active substances or any excipients of PrEP
- 523 ○ taking PEP or other antiretroviral therapy
- 524 • If a patient meets both of the following criteria for possible acute HIV syndrome,
525 they will not be candidates for same-day start:
- 526 ○ High risk exposure to HIV within the past 6 weeks
- 527 ○ Clinical signs and symptoms (currently or within the past 2 weeks) of acute
528 HIV infection, including fever, lymphadenopathy, rash, diarrhea, oral ulcers,
529 myalgia/arthralgia
- 530 ***b) Same-Day-PrEP-Start***
- 531 • If a patient is found eligible for same-day-PrEP start, a 4th generation rapid HIV test
532 needs to be performed.

Shifting PrEP Initiation from Practitioner to Nurse

- 533 ○ If negative, all PrEP initiating labs will be ordered.
- 534 ○ If positive, a 4th generation HIV Antibody/Antigen and HIV viral load test
- 535 should be ordered
- 536 ▪ Patient is referred to Adult HIV Clinic immediately for ART
- 537 • Exclusion criteria for same day PrEP are:
 - 538 ○ Positive HIV test or clinical signs and symptoms of possible acute HIV
 - 539 syndrome, or possible exposure to HIV within the past 72 hours
 - 540 ○ No insurance. Patient will meet with case manager to discuss insurance
 - 541 eligibility.
 - 542 ○ Age >50 years AND no renal function test within the past 6 months on file
 - 543 ○ No working telephone number
- 544 • If patient found to eligible and interested in same-day-PrEP start, 30 days of PrEP will
- 545 be ordered per protocol and pended for signature by the Medical Director.
- 546 • Patient will be counseled that there is a risk that PrEP must be stopped if labs reveal
- 547 any abnormalities, such as renal impairment, in which case patient will receive a call
- 548 by the nurse.
- 549 • If the patient has sexual or drug partners who are known to be HIV infected, the nurse
- 550 should attempt to determine whether these partners are receiving antiretroviral therapy
- 551 and assist with linkage to care for these partners if they are not in care or not receiving
- 552 antiretroviral therapy.
- 553 c) Delayed-PrEP-Start
 - 554 • If decision is made not to start PrEP on the same day routine PrEP initiation labs are
 - 555 ordered:

Shifting PrEP Initiation from Practitioner to Nurse

- 556 ○ If the patient has symptoms consistent with acute HIV infection OR if the patient
- 557 has had a risky exposure (injection drug use, unprotected intercourse) in the last
- 558 three weeks, an HIV viral load test will be drawn, in addition to a 4th generation
- 559 HIV Antibody/Antigen test
- 560 ○ Patients without signs of acute HIV infection, a 4th generation HIV
- 561 Antibody/Antigen test will be drawn
- 562 ○ Patients will be advised to remain abstinent until they begin PrEP.
- 563 ● The nurse will confirm that the patient's calculated creatinine clearance is greater than or
- 564 equal to 60 mL/minute (via Cockcroft-Gault formula).
- 565 ○ If lower than 60 mL/minute, notify Medical Director

566 d) All Patients Starting on PrEP

- 567 ● The nurse will screen for HBV infection and vaccinate against HBV if susceptible, or
- 568 treat if active infection exists, regardless of the decision about prescribing PrEP.
- 569 ● The nurse will screen and coordinate treatment, as needed, for STIs.
- 570 ● The nurse will review and confirm potential drug interactions.
- 571 ● In women of reproductive age or transmales who have sex with males, the nurse will:
- 572 ○ screen for pregnancy with a urine HCG test.
- 573 ○ determine if patient is planning to become pregnant or if patient is breastfeeding.

574 e) Beginning PrEP Medication Regimen

575 After reviewing all lab work to confirm a patient is appropriate for PrEP, the nurse will:

- 576 ● Order 1 tablet of Truvada (TDF 300mg plus FTC 200mg) by mouth daily.
- 577 ○ Prescribe no more than a 90-day supply, renewable only after HIV testing
- 578 confirms that a patient remains HIV-uninfected.

Shifting PrEP Initiation from Practitioner to Nurse

- 579 ○ Route the order to the Medical Director for signing
- 580 ○ If active HBV infection is diagnosed, the nurse will notify Medical Director/
581 refer to Infectious Disease Specialist
- 582 ● Provide risk-reduction and PrEP medication adherence counseling and condoms.
- 583 ● Confirm patient's insurance coverage. Refer uninsured patients or patients with high
584 prescription co-pays to <https://www.pleaseprepme.org/payment>
- 585 ● Place ICD 10 Code on problem list (Encounter for HIV counseling; HIV risk factors
586 affecting pregnancy)
- 587 ● Educate patient:
- 588 ○ About medication side effects and what to do should they occur.
- 589 ▪ Common: diarrhea, dizziness, nausea, headache, fatigue, abnormal dreams,
590 sleep problems, rash, depression.
- 591 ● Continue medication
- 592 ● Contact care team to discuss symptoms
- 593 ● Schedule an evaluation within one week of contact with care team
- 594 ▪ Serious: lactic acidosis (weakness, unusual pain, trouble breathing, nausea,
595 vomiting, fast heartbeat, feeling cold/dizzy/lightheaded), liver problems
596 (jaundice, biliuria, light colored stools, lack of appetite, nausea, abdominal
597 pain).
- 598 ● Discontinue medication
- 599 ● Contact care team to discuss symptoms that day
- 600 ● Schedule an evaluation within 24 hours of contact with care team

Shifting PrEP Initiation from Practitioner to Nurse

- 601 ○ About acute HIV infection symptoms (fever, malaise, myalgia, rash, headache,
602 night sweats, sore throat, lymphadenopathy), and what to do if these should occur.

603 *f) Monitoring During Treatment*

604 While on PrEP, the patient should be evaluated by the nurse one month after PrEP initiation and
605 every 3 months thereafter. These quarterly visits shall include:

- 606 • Confirmation of HIV-negative status. This will entail obtaining a 4th generation HIV
607 Antibody/Antigen test (and an HIV VL if the patient is symptomatic for acute HIV
608 infection).
- 609 • Evaluation of PrEP medication adherence.
- 610 • Assessment of risk behaviors and provision of risk-reduction counseling and
611 condoms.
- 612 • Assessment of STI symptoms and, if present, testing and treatment for STIs, as
613 needed (at least every six months).
- 614 • Three months after initiation, then every six months while on PrEP medication,
615 BUN and serum creatinine should be checked.
- 616 • In women of reproductive age and trans-males, a pregnancy test and, if pregnant,
617 discussion of continued use of PrEP with patient.

618